Frank R Lichtenberg

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi Effects of new drugs on overall health spending: Frank Lichtenberg responds
    Frank R Lichtenberg
    Columbia University, New York City, USA
    Health Aff (Millwood) 26:887-90. 2007
  2. doi The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009
    Frank R Lichtenberg
    Columbia University, United States National Bureau of Economic Research, United States Electronic address
    Econ Hum Biol 13:107-27. 2014
  3. doi The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY, USA
    Eur J Health Econ 14:41-56. 2013
  4. doi Is home health care a substitute for hospital care?
    Frank R Lichtenberg
    Columbia University, Graduate School of Business, New York, New York 10027, USA
    Home Health Care Serv Q 31:84-109. 2012
  5. doi Contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001-7
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY 10027, USA
    Pharmacoeconomics 30:197-211. 2012
  6. doi Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York City, NY, USA
    Health Aff (Millwood) 30:1539-44. 2011
  7. ncbi The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate US time-series data
    Frank R Lichtenberg
    Professor, Graduate School of Business, Columbia University and Research Associate, National Bureau of Economic Research Mailing address 614 Uris Hall, 3022 Broadway, New York, NY 10027, USA
    Expert Rev Pharmacoecon Outcomes Res 6:425-36. 2006
  8. doi Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY, USA
    Health Econ 18:519-34. 2009
  9. ncbi The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997 to 2003
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY 10027, USA
    Pharmacoeconomics 24:5-25. 2006
  10. ncbi Pharmaceutical innovation and the burden of disease in developing and developed countries
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, New York 10027, USA
    J Med Philos 30:663-90. 2005

Detail Information

Publications25

  1. ncbi Effects of new drugs on overall health spending: Frank Lichtenberg responds
    Frank R Lichtenberg
    Columbia University, New York City, USA
    Health Aff (Millwood) 26:887-90. 2007
    ..Their description of my methodology is quite inaccurate, and they ignored some previous evidence of large cost offsets based on an entirely different methodology (analysis of longitudinal group-level data) not subject to their critique...
  2. doi The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009
    Frank R Lichtenberg
    Columbia University, United States National Bureau of Economic Research, United States Electronic address
    Econ Hum Biol 13:107-27. 2014
    ..This estimate is fairly close to the mean of estimates obtained ($10,800) from U.S., German, and Australian studies. ..
  3. doi The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY, USA
    Eur J Health Econ 14:41-56. 2013
    ..6%. The reduction in the French growth rate of PYLL65 attributable to lagged new drug approvals was 1.1%. Earlier access to orphan drugs could result in earlier reductions in premature mortality from rare diseases...
  4. doi Is home health care a substitute for hospital care?
    Frank R Lichtenberg
    Columbia University, Graduate School of Business, New York, New York 10027, USA
    Home Health Care Serv Q 31:84-109. 2012
    ..The estimated reduction in 2008 hospital costs resulting from the rise in the fraction of hospital patients discharged to home health care may have been 36% larger than the increase in the payroll of the home health care industry...
  5. doi Contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001-7
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY 10027, USA
    Pharmacoeconomics 30:197-211. 2012
    ..The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer mortality rates, and may have accounted for as much as half of the decline...
  6. doi Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York City, NY, USA
    Health Aff (Millwood) 30:1539-44. 2011
    ..Although reducing price discrimination in order to cut costs might benefit consumers in the short run, it would harm them in the long run by reducing the number of new drugs developed...
  7. ncbi The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate US time-series data
    Frank R Lichtenberg
    Professor, Graduate School of Business, Columbia University and Research Associate, National Bureau of Economic Research Mailing address 614 Uris Hall, 3022 Broadway, New York, NY 10027, USA
    Expert Rev Pharmacoecon Outcomes Res 6:425-36. 2006
    ....
  8. doi Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY, USA
    Health Econ 18:519-34. 2009
    ..However, our estimate of the increase in expenditure on cardiovascular hospital stays is about 3.7 times as large as our estimate of the reduction in per capita expenditure for cardiovascular drugs that would have occurred ($24)...
  9. ncbi The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997 to 2003
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY 10027, USA
    Pharmacoeconomics 24:5-25. 2006
    ....
  10. ncbi Pharmaceutical innovation and the burden of disease in developing and developed countries
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, New York 10027, USA
    J Med Philos 30:663-90. 2005
    ....
  11. ncbi Availability of new drugs and Americans' ability to work
    Frank R Lichtenberg
    Columbia University, New York, New York 10027, USA
    J Occup Environ Med 47:373-80. 2005
    ....
  12. ncbi The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, National Bureau of Economic Research, 614 Uris Hall, 3022 Broadway, New York, NY 10027, USA
    Int J Health Care Finance Econ 5:47-73. 2005
    ....
  13. ncbi The effect of access restrictions on the vintage of drugs used by Medicaid enrollees
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY 10027, USA
    Am J Manag Care 11:SP7-13. 2005
    ..To examine the extent to which recent Medicaid drug access restrictions, such as preferred drug lists (PDLs), may affect the vintage (or time since Food and Drug Administration approval) of 6 types of drugs used by Medicaid beneficiaries...
  14. ncbi The effect of new drug approvals on HIV mortality in the US, 1987-1998
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, 726 Uris Hall, 3022 Broadway, New York, NY 10027, USA
    Econ Hum Biol 1:259-66. 2003
    ..The annual number of HIV deaths is estimated to have been reduced by over 6000, on average, by an additional HIV drug approval. The social return to HIV drug innovation appears to be extremely large...
  15. doi The quality of medical care, behavioral risk factors, and longevity growth
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, 3022 Broadway, 504 Uris Hall, New York, NY 10027, USA
    Int J Health Care Finance Econ 11:1-34. 2011
    ..Controlling for the adoption of an important nonmedical innovation also has little influence on the estimated effects of medical innovation adoption on life expectancy...
  16. ncbi Pharmaceutical innovation and the longevity of Australians: a first look
    Frank R Lichtenberg
    Columbia University, New York, NY, USA
    Adv Health Econ Health Serv Res 19:95-117. 2008
    ..The value of this paper's evidence is primarily due to the government's Pharmaceutical Benefits Scheme: Australia has much better data on drug utilization than most other countries...
  17. ncbi The economic and human impact of new drugs
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY 10027, USA
    J Clin Psychiatry 64:15-8. 2003
    ..Further, new drugs contribute to health and economic growth in the United States. Formularies, to the extent that they restrict drug choices, restrict access to new drugs...
  18. doi The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY, USA
    Value Health 12:847-56. 2009
    ..Others suggest that the opposite is true--new drugs offer good value for money and are well worth the cost. To provide evidence on this issue, we evaluated the impact of drug innovation on the longevity of Canadians...
  19. ncbi The effect of drug vintage on survival: micro evidence from Puerto Rico's Medicaid program
    Frank R Lichtenberg
    Graduate School of Business, Columbia University, New York, NY, USA
    Adv Health Econ Health Serv Res 22:273-92. 2010
    ..The actual mortality rate is about 16% (3.7% vs. 4.4%) lower than it would have been if all of the drugs utilized in 2000 had been pre-1970 drugs. Estimates for subgroups of people with specific diseases display the same general pattern...
  20. ncbi The impact of Medicare Part D on prescription drug use by the elderly
    Frank R Lichtenberg
    Columbia University in New York City, USA
    Health Aff (Millwood) 26:1735-44. 2007
    ..This does not necessarily mean that Medicare Part D is an economically inefficient program...
  21. doi The impact of therapeutic procedure innovation on hospital patient longevity: evidence from Western Australia, 2000-2007
    Frank R Lichtenberg
    Columbia University, National Bureau of Economic Research, 504 Uris Hall, 3022 Broadway, New York, NY 10027, USA
    Soc Sci Med 77:50-9. 2013
    ..In either case, therapeutic procedure innovation in WA hospitals appears to have been remarkably cost-effective, because it increased the cost of medical procedures by a negligible amount...
  22. ncbi The effect of pharmaceutical innovation on the functional limitations of elderly americans: evidence from the 2004 National Nursing Home Survey
    Frank R Lichtenberg
    Columbia University Graduate School of Business, New York, NY, USA
    Adv Health Econ Health Serv Res 23:73-101. 2012
    ..To examine the effect of pharmaceutical innovation on the functional status of nursing home residents...
  23. doi What are the respective roles of the public and private sectors in pharmaceutical innovation?
    Bhaven N Sampat
    Department of Health Policy and Management, School of Public Health, Columbia University, New York City, NY, USA
    Health Aff (Millwood) 30:332-9. 2011
    ..Our analyses should help inform thinking about the returns on public research funding-a topic of long-standing interest to economists, policy makers, and health advocates...
  24. ncbi On "New Cardiovascular Drugs: Pattern of Use and Association with Non-Drug Health Expenditures"
    Frank R Lichtenberg
    Inquiry 43:80-2; author reply 82-4. 2006
  25. ncbi New drugs and lower costs
    Frank R Lichtenberg
    Am J Health Syst Pharm 59:1894-5; author reply 1895. 2002